Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:AGN
CUSIP01849010
Phone862-261-7000
Debt
Debt-to-Equity Ratio0.34
Current Ratio1.00
Quick Ratio0.85
Price-To-Earnings
Trailing P/E Ratio11.35
Forward P/E Ratio11.40
P/E Growth1.38
Sales & Book Value
Annual Sales$15.94 billion
Price / Sales3.95
Cash Flow$40.4357 per share
Price / Cash4.59
Book Value$207.19 per share
Price / Book0.90
Profitability
EPS (Most Recent Fiscal Year)$16.35
Net Income$-4,125,500,000.00
Net Margins-10.29%
Return on Equity8.60%
Return on Assets5.23%
Miscellaneous
Employees17,800
Outstanding Shares339,440,000
Market Cap$62.46 billion
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan declared a quarterly dividend on Monday, July 30th. Investors of record on Friday, August 17th will be given a dividend of $0.72 per share on Monday, September 17th. This represents a $2.88 annualized dividend and a yield of 1.55%. The ex-dividend date of this dividend is Thursday, August 16th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan announced that its Board of Directors has authorized a share buyback program on Tuesday, September 26th 2017, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) announced its quarterly earnings data on Thursday, July, 26th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $4.13 by $0.29. The firm had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $3.92 billion. Allergan had a negative net margin of 10.29% and a positive return on equity of 8.60%. Allergan's quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $4.02 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
What guidance has Allergan issued on next quarter's earnings?
Allergan updated its FY18 earnings guidance on Thursday, July, 26th. The company provided earnings per share guidance of $16.00-16.50 for the period, compared to the Thomson Reuters consensus estimate of $16.08. The company issued revenue guidance of $15.45-15.6 billion, compared to the consensus revenue estimate of $15.31 billion.Allergan also updated its Q3 guidance to $3.80-4.10 EPS.
What price target have analysts set for AGN?
21 brokerages have issued 12-month target prices for Allergan's stock. Their forecasts range from $160.07 to $265.00. On average, they anticipate Allergan's stock price to reach $212.3195 in the next year. This suggests a possible upside of 14.4% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)
- 2. According to Zacks Investment Research, "2018 could prove to be a tough year for Allergan with the company facing loss of exclusivity for many products including Namenda XR and Restasis. Also, new competition for key growth drivers, Restasis and Linzess, is a concern. Nonetheless, Allergan boasts dominant growth franchises across several therapeutic areas. Key products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar will continue to support sales. Allergan also boasts a strong branded pipeline with meaningful data readouts expected in 2018. Biosimilars also represent significant opportunity. In late 2017, Allergan announced cost-cutting efforts to protect it from potential revenue declines. Allergan’s share price has picked up after underperforming the industry in the second half of 2017. Estimates have gone up ahead of the Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/24/2018)
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG) and Vertex Pharmaceuticals (VRTX).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Has Allergan been receiving favorable news coverage?
News stories about AGN stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Allergan earned a media and rumor sentiment score of 0.22 on Accern's scale. They also assigned headlines about the company an impact score of 49.31 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Allergan.
Who are Allergan's major shareholders?
Allergan's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (1.73%), Edgewood Management LLC (1.69%), Janus Henderson Group PLC (1.41%), Bank of New York Mellon Corp (1.05%), Senator Investment Group LP (0.68%) and Morgan Stanley (0.64%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which major investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cantillon Capital Management LLC, Macquarie Group Ltd., Epoch Investment Partners Inc., Iridian Asset Management LLC CT, Swedbank, Point72 Asset Management L.P. and Jennison Associates LLC. View Insider Buying and Selling for Allergan.
Which major investors are buying Allergan stock?
AGN stock was bought by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Janus Henderson Group PLC, Orbimed Advisors LLC, Longview Partners Guernsey LTD, Wedge Capital Management L L P NC, Cornerstone Wealth Management LLC and HL Financial Services LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $185.60.
How big of a company is Allergan?
Allergan has a market capitalization of $62.46 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
